Previous research from our group implicated PRMT3 in oxaliplatin resistance through IGF2BP1 methylation,[13] with IGF2BP1 being implicated in chemoresistance across several cancer types.[24, 25, 26] We speculate IGF2BP1 may partly mediates chemoresistance in rectal cancer. Here, IGF2BP1 is linked to rectal cancer.